176 related articles for article (PubMed ID: 19435893)
1. Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer.
Miller TW; Pérez-Torres M; Narasanna A; Guix M; Stål O; Pérez-Tenorio G; Gonzalez-Angulo AM; Hennessy BT; Mills GB; Kennedy JP; Lindsley CW; Arteaga CL
Cancer Res; 2009 May; 69(10):4192-201. PubMed ID: 19435893
[TBL] [Abstract][Full Text] [Related]
2. PTEN insufficiency modulates ER+ breast cancer cell cycle progression and increases cell growth in vitro and in vivo.
Chiang KC; Chen HY; Hsu SY; Pang JH; Wang SY; Hsu JT; Yeh TS; Chen LW; Kuo SF; Sun CC; Lee JM; Yeh CN; Juang HH
Drug Des Devel Ther; 2015; 9():4631-8. PubMed ID: 26316702
[TBL] [Abstract][Full Text] [Related]
3. Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer.
Miller TW; Balko JM; Arteaga CL
J Clin Oncol; 2011 Nov; 29(33):4452-61. PubMed ID: 22010023
[TBL] [Abstract][Full Text] [Related]
4. Abrogating endocrine resistance by targeting ERα and PI3K in breast cancer.
Fox EM; Arteaga CL; Miller TW
Front Oncol; 2012; 2():145. PubMed ID: 23087906
[TBL] [Abstract][Full Text] [Related]
5. Treatment of PTEN-Null Breast Cancer by a Synthetic Lethal Approach Involving PARP1 Gene Silencing.
Asai T; Yokota M; Isomura H; Koide H; Sakurai N; Okamoto A; Ando H; Dewa T; Oku N
J Pharm Sci; 2023 Jul; 112(7):1908-1914. PubMed ID: 36828124
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic targeting of cancers with loss of PTEN function.
Dillon LM; Miller TW
Curr Drug Targets; 2014 Jan; 15(1):65-79. PubMed ID: 24387334
[TBL] [Abstract][Full Text] [Related]
7. Adult-onset deletion of Pten increases islet mass and beta cell proliferation in mice.
Yang KT; Bayan JA; Zeng N; Aggarwal R; He L; Peng Z; Kassa A; Kim M; Luo Z; Shi Z; Medina V; Boddupally K; Stiles BL
Diabetologia; 2014 Feb; 57(2):352-61. PubMed ID: 24162585
[TBL] [Abstract][Full Text] [Related]
8. ΔNp63 is regulated by insulin/IGF-1 signaling in normal basal/progenitor mammary cells and in luminal-type breast cancer cells.
Stenckova M; Liu Y; Nekulova M; Holcakova J; Pokorna Z; Nenutil R; Thompson AM; Vojtesek B; Coates PJ
Neoplasma; 2023 Oct; 70(5):621-632. PubMed ID: 38053383
[TBL] [Abstract][Full Text] [Related]
9. The biochemical and clinical implications of phosphatase and tensin homolog deleted on chromosome ten in different cancers.
Wang Q; Wang J; Xiang H; Ding P; Wu T; Ji G
Am J Cancer Res; 2021; 11(12):5833-5855. PubMed ID: 35018228
[TBL] [Abstract][Full Text] [Related]
10. Prognostic and Predictive Implications of PTEN in Breast Cancer: Unfulfilled Promises but Intriguing Perspectives.
Carbognin L; Miglietta F; Paris I; Dieci MV
Cancers (Basel); 2019 Sep; 11(9):. PubMed ID: 31546901
[TBL] [Abstract][Full Text] [Related]
11. SUMO, PTEN and Tumor Suppression.
Matunis MJ; Guzzo CM
Pigment Cell Melanoma Res; 2012 Jul; ():. PubMed ID: 22846175
[TBL] [Abstract][Full Text] [Related]
12. ERα-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer.
Miller TW; Balko JM; Fox EM; Ghazoui Z; Dunbier A; Anderson H; Dowsett M; Jiang A; Smith RA; Maira SM; Manning HC; González-Angulo AM; Mills GB; Higham C; Chanthaphaychith S; Kuba MG; Miller WR; Shyr Y; Arteaga CL
Cancer Discov; 2011 Sep; 1(4):338-51. PubMed ID: 22049316
[TBL] [Abstract][Full Text] [Related]
13. PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer.
Glaviano A; Foo ASC; Lam HY; Yap KCH; Jacot W; Jones RH; Eng H; Nair MG; Makvandi P; Geoerger B; Kulke MH; Baird RD; Prabhu JS; Carbone D; Pecoraro C; Teh DBL; Sethi G; Cavalieri V; Lin KH; Javidi-Sharifi NR; Toska E; Davids MS; Brown JR; Diana P; Stebbing J; Fruman DA; Kumar AP
Mol Cancer; 2023 Aug; 22(1):138. PubMed ID: 37596643
[TBL] [Abstract][Full Text] [Related]
14. Plasma microRNA ratios associated with breast cancer detection in a nested case-control study from a mammography screening cohort.
Chiorino G; Petracci E; Sehovic E; Gregnanin I; Camussi E; Mello-Grand M; Ostano P; Riggi E; Vergini V; Russo A; Berrino E; Ortale A; Garena F; Venesio T; Gallo F; Favettini E; Frigerio A; Matullo G; Segnan N; Giordano L
Sci Rep; 2023 Jul; 13(1):12040. PubMed ID: 37491482
[TBL] [Abstract][Full Text] [Related]
15. Overview of the therapeutic strategies for ER positive breast cancer.
Blakely B; Shin S; Jin K
Biochem Pharmacol; 2023 Jun; 212():115552. PubMed ID: 37068524
[TBL] [Abstract][Full Text] [Related]
16. ER+, HER2- advanced breast cancer treated with taselisib and fulvestrant: genomic landscape and associated clinical outcomes.
Chen JW; Jacot W; Cortés J; Krop IE; Dent S; Harbeck N; De Laurentiis M; Diéras V; Im YH; Stout TJ; Schimmoller F; Savage HM; Hutchinson KE; Wilson TR
Mol Oncol; 2023 Oct; 17(10):2000-2016. PubMed ID: 36892268
[TBL] [Abstract][Full Text] [Related]
17. GDNF-RET signaling and EGR1 form a positive feedback loop that promotes tamoxifen resistance via cyclin D1.
Marks BA; Pipia IM; Mukai C; Horibata S; Rice EJ; Danko CG; Coonrod SA
BMC Cancer; 2023 Feb; 23(1):138. PubMed ID: 36765275
[TBL] [Abstract][Full Text] [Related]
18. Prolylcarboxypeptidase promotes IGF1R/HER3 signaling and is a potential target to improve endocrine therapy response in estrogen receptor positive breast cancer.
Duan L; Calhoun SJ; Perez RE; Macias V; Mir F; Gattuso P; Maki CG
Cancer Biol Ther; 2022 Dec; 23(1):1-10. PubMed ID: 36332175
[TBL] [Abstract][Full Text] [Related]
19. HER3 in cancer: from the bench to the bedside.
Gandullo-Sánchez L; Ocaña A; Pandiella A
J Exp Clin Cancer Res; 2022 Oct; 41(1):310. PubMed ID: 36271429
[TBL] [Abstract][Full Text] [Related]
20. Exploring new pathways in endocrine-resistant breast cancer.
de Pinho IS; Abreu C; Gomes I; Casimiro S; Pacheco TR; de Sousa RT; Costa L
Explor Target Antitumor Ther; 2022; 3(3):337-361. PubMed ID: 36045911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
